RecruitingNCT07608003

Application of MRI-Based Artificial Intelligence Models for Preoperative Molecular Subtyping and Prognostic Assessment of Midline Gliomas: A Multicenter Prospective Clinical Study

Sponsor: Xiangya Hospital of Central South University

Trial Details

Condition	Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem, Glioma, Diffuse Midline, H3K27M-mutant, Glioma : Oligodendroglioma or Astrocytoma, Gliomas
Status	Recruiting
Participants	500
Est. Completion	31 Dec 2030
Last Updated	27 May 2026

Primary Outcome

Diagnostic accuracy for midline glioma molecular subtypes

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Patients with diffuse gliomas were pathologically and molecularly diagnosed. * The clinical case data of all patients were complete. * Patients underwent preoperative MRI examination. Exclusion Criteria: * The tumor is not located in the intracranial midline. * Cases in which MRI were incomplete or with significant noise and artifacts.

Trial Sites

Countries

China

View Registry Entry

Related Analysis

Multicenter Trial Tests AI-Enhanced MRI for Preoperative Glioma Molecular Subtyping — Potential to Transform Neurosurgical Planning

A multicenter Chinese trial is validating an AI model that uses preoperative MRI to predict critical molecular markers in midline gliomas, potentially revolutionizing non-invasive diagnosis and treatment planning. The study aims to eliminate the need for risky biopsies in eloquent brain regions.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service